Blau Farmacêutica S.A. (BOVESPA: BLAU3)
Health Care · Biotechnology · BR
R$8.96
-0.67% today · -6.7% 1Y
Blau Farmacêutica S.A. (BOVESPA: BLAU3) operates in the Biotechnology industry within the Health Care sector. The company is valued at $401.07M and employs 1,900 people.
Over the last twelve months the share price has lost 6.7%, trading between 8.28 and 11.84.
Tweenvest scores Blau Farmacêutica S.A. across four factors: quality 70/100, value 80/100, growth 65/100, dividend 75/100. Its strongest factor is value.
BLAU3 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $401.07M
- Revenue (TTM)
- $344.76M
- P/E
- 8.90
- EPS
- 1.01
- Dividend yield
- 3.96%
- Beta (5Y)
- 0.46
- 52-week high
- R$11.84
- 52-week low
- R$8.28
- Avg volume (3M)
- —
- Shares outstanding
- 230.98M
- Employees
- 1,900
- Next earnings
- —
About Blau Farmacêutica S.A.
Blau Farmacêutica S.A. operates as a pharmaceutical enterprise, supplying private label medications across Brazil, Argentina, Colombia, the United States, Ecuador, Peru, and Uruguay. Its extensive product portfolio encompasses a broad spectrum of therapeutic areas, including immunology, hematology, oncology, nephrology, specialized treatments, and antibiotics. The company's offerings also extend to biological drugs, oral and injectable therapies for cancer, specialized treatments for infectious diseases, and a range of prescription and over-the-counter products like dermo-medicines and contraceptives, catering to both retail and non-retail markets. Additionally, Blau provides pharmaceuticals derived from blood, biological and biotechnological agents, and antiretroviral drugs. Its client base includes hospitals, private medical clinics, chemotherapy and hemodialysis centers, and public health institutions. Established in 1987, the firm's corporate headquarters are situated in Cotia, Brazil.
- ISIN
- BRBLAUACNOR8
- Founded
- 1987
- Listed since
- Apr 19, 2021
- Exchange
- Bolsa de Valores de Sao Paulo
- Currency
- BRL
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.74 | -0.02% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €909.60 | +3.46% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $157.49 | -0.84% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.